

Mucosal CD8 Memory T Cells are selected in the periphery by an MHC Class I Molecule

Yujun Huang^{1*}, Yunji Park^{1*}, Yiran Wang-Zhu¹, Alexandre Lorange¹, Ramon Arens¹, Iván Bernardo^{1,2}, Danyvid Olivares-Villagómez³, Dietmar Herndler-Brandstetter⁴, Ninan Abraham⁵, Beatrix Grubeck-Loebenstein⁴, Stephen P. Schoenberger¹, Luc Van Kaer³, Mitchell Kronenberg¹, Michael A. Teitell⁶ and Hilde Cheroutre¹

1. Division of Developmental Immunology, La Jolla Institute for Allergy & Immunology, La Jolla, CA 92037, USA.

2. Current address: Clinical Laboratory. Histocompatibility Section, San Pedro Hospital. Calle Piqueras, 98 - 26006 - Logroño, Spain

3. Department of Microbiology & Immunology, Vanderbilt University, School of Medicine, Nashville, TN 37232, USA.

4. Division of Immunology, Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.

5. Department of Microbiology and Immunology, Life Sciences Institute, 3552 - 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.

6. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA.

*These authors contributed equally to this work.

This is manuscript 1063 from the La Jolla Institute for Allergy and Immunology.

The presence of immune memory at pathogen entry sites is a prerequisite for protection. Nevertheless, the mechanisms that warrant immunity at peripheral interfaces are not understood. Here we show that the non-classical MHC class I molecule, the thymus leukemia antigen (TL), induced on dendritic cells together with CD8 α on activated CD8 α β ⁺T cells, mediates affinity-based selection of memory precursor cells. Furthermore, constitutive expression of TL on epithelial cells continues the selection of mature CD8 α β memory T cells. The TL-CD8 α -driven memory process is essential for the generation of memory CD8 α β T cells in the intestine and leads to the accumulation of highly antigen sensitive CD8 α β memory T cells that form the first line of defense at the largest entry port for pathogens.

A hallmark of immune memory is that repeated infections are met with accelerated and enhanced protective immunity¹. Furthermore, unlike naïve T lymphocytes, or central memory T cells (T_{CM}), that reside in lymphoid tissues, some antigen-experienced T cells gain the capacity to persist long-term as effector memory T cells (T_{EM}) in non-lymphoid tissues, such as the intestine²⁻⁵. T_{CM} cells, which respond with a robust clonal expansion, are effective at protecting against infections by pathogens that replicate systemically⁶, but they likely are inadequate to prevent transmission of viruses, including the human immunodeficiency virus (HIV), or intracellular bacteria, which penetrate across mucosal epithelia^{3,7}. Effective resistance against transmission of such pathogens requires the presence of local antigen-specific T_{EM} prior to re-challenge⁷. Therefore, strategies aimed at inducing a powerful protective immune response that also warrants the formation of pre-existing mucosal antigen-specific T_{EM} are considered an essential goal of successful vaccinations.

Listeria monocytogenes (Lm), a Gram-positive intracellular pathogen of human and other mammals including mice, is a food borne pathogen, which upon ingestion and uptake by phagocytic cells, such as monocytes and dendritic cells (DC) disseminate from the intestine into the bloodstream and spread to various systemic tissues such as the liver⁸. In humans, ingested Lm may cause listeriosis because of its ability to also infect non-phagocytic cells such as the intestinal epithelial cells (IEC) through interaction of the molecule internalin expressed by the Lm and human E-cadherin expressed on the baso-lateral pole of the enterocytes⁹. Mice, by contrast, when infected orally do not develop listeriosis due to the inability of Lm internalin to interact with mouse E-cadherin. Instead, mice clear the infection of ingested bacteria with an effective CD8-dependent protective immune response, although bacteria that crossed the mucosal barrier can spread to the liver and other organs via the blood, as can occur in humans⁸. These observations have important implications for immunization strategies and indicate that the presence of local pre-existing mucosal immunity might be key for the induction of effective protective immunity against food borne pathogens. Despite this however, most of the current knowledge of immune memory has been gained from model systems that use systemic immunization routes and memory generation in lymphoid tissues. Although such pre-existing immunity might be highly effective to combat pathogens that enter the body systemically, it is most likely inadequate to prevent entry and systemic spreading of pathogens, which invade via the mucosal route of the intestine. Because mice can be infected by the oral route similarly to humans and because of the protective endogenous mucosal CD8-mediated immune response that is generated in mice in response to ingested bacteria, together with the emergence of genetically manipulated avirulent attenuated wild type- and recombinant (ActA⁻) Lm strains as important vectors for vaccinations^{8, 10, 11}, immunizations of mice with Lm introduced via the oral route represent an optimal approach to

examine mechanisms and conditions that lead to the generation of effective pre-existing mucosal immune memory.

We showed previously that CD8 homodimers (CD8 $\alpha\alpha$), induced on activated CD8 $\alpha\beta$ T cells, which maintain expression of CD8 $\alpha\beta$, mark those primary effector cells that preferentially differentiate to memory cells¹². In mice, memory CD8 $\alpha\beta$ T cells that co-express CD8 $\alpha\alpha$ are greatly enriched in the epithelium of the intestine¹³. In that same location, the high affinity ligand for CD8 $\alpha\alpha$ ¹⁴, a non-classical, nonpolymorphic MHC class I molecule, known as the thymus leukemia antigen but hereafter called TL, is constitutively expressed on the adjacent epithelial cells^{15,16}. This suggests a role for epithelial TL in the accumulation of mucosal CD8 $\alpha\alpha^+$ CD8 $\alpha\beta$ memory T cells, however the mechanisms that drive the CD8 $\alpha\alpha$ -dependent generation of mucosal immune memory remained unknown.

Using the oral Lm infection model to elicit a CD8-driven protective immune response initiated at the mucosal entry site, we define here a novel, affinity-based selection mechanism controlled by TL expression, induced on antigen presenting cells (APC), that leads to the survival and differentiation of high affinity, CD8 $\alpha\alpha^+$ CD8 $\alpha\beta$ memory precursor cells. Furthermore, the data also indicate that the constitutive expression of TL on the epithelium of the intestine continues to impose selection pressure, which contributes to the affinity maturation of the resident mucosal CD8 $\alpha\beta$ T_{EM}.

RESULTS

TL is not required for the formation of memory CD8 $\alpha\beta^+$ T cells.

Considering the class I-like antigen presenting molecules in the mouse genome, TL is distinguished because it has a particularly high affinity for CD8 $\alpha\alpha$, due to unique amino acids

substitutions at three positions in the membrane proximal $\alpha 3$ domain¹⁷. To assess if TL, the most likely physiologic ligand for CD8 α *in vivo*¹², also plays a role in the generation of CD8 $\alpha\beta$ effector memory cells, we analyzed CD8 $\alpha\beta$ T cell memory differentiation in TL gene (*T3^b*) knock out (TL^{-/-}) mice¹⁸. The absence of TL did not impair, but rather enhanced, the generation of OVA-specific CD8 $\alpha\beta$ memory T cells in the spleen of TL^{-/-} mice infected orally with Lm bacteria expressing OVA antigen (Lm-OVA) (**Fig. 1a**). A similar effect was observed in the epithelium of the intestine when intraepithelial lymphocytes (IEL) were analyzed (**Fig. 1a**). Likewise, naïve OVA peptide (OVA_p) and H-2K^b specific monoclonal TCR transgenic OT-I T cells transferred to WT or TL^{-/-} recipient mice that were subsequently orally infected with Lm-OVA also generated more OT-I TCR transgenic memory T cells in the absence of TL expression (**Fig. 1b**). These observations are consistent with previous published data using single chain MHC class I transgenic mice on a $\beta 2m$ deficient background, which also indicated that in the absence of TL, normal or slightly enhanced memory formed in response to a viral infection¹⁹. All together, the data show that, whereas CD8 α promotes memory differentiation of CD8 $\alpha\beta$ ⁺ effector T cells¹², its high-affinity ligand TL, appears to inhibit this process.

TL negatively affects memory generation of CD8 $\alpha\beta$ -effector cells.

TL has a restricted pattern of expression²⁰ that includes induction on antigen presenting cells (APC), such as DC, in addition to expression on epithelial cells¹². The increase in memory CD8 $\alpha\beta$ ⁺ T cells seen in the absence of TL in TL^{-/-} mice suggests that, under normal conditions, TL expression on subsets of priming DC might negatively influence survival or differentiation of CD8 $\alpha\beta$ memory precursor cells. To test this possibility, we analyzed the effect of constitutive TL expression during priming using TL transgenic (TL-Tg) mice, which express an allelic form of TL

(*T18^d*) under the control of the promoter from the MHC class I molecule, *H-2D^d*. In contrast to the outcome in *TL^{-/-}* hosts, transferred OT-I T cells which were primed *in vivo* in *TL-Tg* recipient mice that were orally infected with Lm-OVA failed to generate or sustain immune memory, either locally in the intestine or systemically, including in the spleen and liver (**Fig. 1c** and **Supplementary Fig. 1**). Moreover, OT-I T cells primed systemically *in vivo* using *TL-Tg* OVAp-loaded bone marrow (BM) DC that were adoptively transferred failed to generate memory cells in the spleen of WT hosts (**Fig. 1d**). Similarly, OT-I cells initially primed *in vitro* by *TL-Tg* OVAp-expressing APC, did not generate memory cells following adoptive transfer (**Fig. 1d**). These data indicate that TL expression on APC interferes with the survival and memory programming of primary $CD8\alpha\beta^+$ effector cells.

Under steady state conditions resting spleen DC normally do not express detectable levels of TL surface protein, although some induce it upon activation¹². However, an analysis of different DC subsets indicated that in contrast to spleen DC, a subset of mesenteric lymph node (mLN) DC constitutively express a low level of TL. This TL^+ subset has the phenotype of mature migratory DC (MHC class II^{high}/CD11c⁺ and CD103⁺CCR7⁺) (**Supplementary Fig. 2a**), which is also typical of those DC that drive retinoic acid (RA)-based induction of gut homing receptors on the T cells they prime²¹, (**Fig. 1e** and **Supplementary Fig. 2b**). The expression of TL on these mucosal DC was further upregulated during priming, and greatly enhanced in response to innate immune stimuli such as CpG oligodeoxynucleotides (**Fig. 1f**). These observations indicate that naïve T cells responding *in vivo* to gut-derived antigens are primed in the context of TL, expressed by the migratory DC and greatly upregulated under inflammatory conditions.

TL induces Fas-mediated death of activated $CD8\alpha\beta^+$ T cells.

Although TL displays structural characteristics of MHC class I molecules, it does not function as a typical antigen-presenting molecule. The narrow distance between the α helices that form the boundaries of the antigen binding groove will not permit TL peptide binding and presentation²² and therefore TL fails to engage with the $\alpha\beta$ TCR. Nevertheless the high degree of conserved sequence in the $\alpha 3$ domain allows TL to interact with the CD8 $\alpha\beta$ co-receptor, despite the exclusion of TL from the TCR activation complex¹⁴. A similar interaction of soluble HLA class I molecules with CD8 $\alpha\beta$ TCR co-receptor, separately from TCR ligation, was previously shown to lead to Fas-FasL-induced cell death²³⁻²⁶. To investigate if the TL interaction with CD8 $\alpha\beta$ on activated T cells might also lead to cell death, we measured the survival of naïve and antigen stimulated CD8 $\alpha\beta^+$ cells in the presence of constitutive TL expression in TL-Tg hosts. Whereas naïve donor cells survived similarly in WT or TL-Tg mice, activated CD8 $\alpha\beta^+$ OT-I cells survived only in WT but not in TL-Tg hosts (**Fig. 2a**), supporting the notion that TL-induced cell death (TICD) targets activated CD8 $\alpha\beta^+$ T cells. Activated Fas-deficient^{*lpr/lpr*} CD8 $\alpha\beta^+$ donor T cells, however, were not deleted in TL-Tg recipient mice, providing evidence that, similar to the reported death by soluble HLA-G^{23,24}, TICD also involves the Fas/FasL-mediated death pathway (**Fig. 2b**).

Activation-induced CD8 α rescues CD8 $\alpha\beta$ effector T cells.

In contrast to CD8 $\alpha\beta$, CD8 α does not function as a TCR co-receptor and similar to TL, CD8 α also does not engage in the TCR activation complex^{27,28}. However, whereas TL induces death of activated CD8 $\alpha\beta^+$ T cells, CD8 α , which exhibits a stronger affinity for TL compared to CD8 $\alpha\beta$ ¹⁴, promotes the survival of CD8 $\alpha\beta$ effector cells¹², suggesting that activation-induced CD8 α might interfere with TICD. To test this, we compared the survival and memory differentiation of CD8 $\alpha\beta$ effector T cells in the absence or presence of CD8 α . Due to a deletion

of CD8 α enhancer region I (E8 $_I^{-/-}$)²⁹, OT-I CD8 $\alpha\beta$ donor cells on the E8 $_I^{-/-}$ background (E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$) do not induce detectable levels of activation-dependent CD8 $\alpha\alpha$ ¹². When analyzed *in vitro*, E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$ T cells primed by OVA-loaded mLN DC, which constitutively express TL (Fig. 1e), showed increased activation induced death compared to their counterparts primed by spleen DC (Fig. 3a). However, the increase in cell death induced by these mucosal APC was not observed when mLN and spleen DC isolated from TL $^{-/-}$ mice were compared (Fig. 3a).

Furthermore, similar to our previous published results showing impaired spleen memory generation by E8 $_I^{-/-}$ CD8 $\alpha\beta$ T cells in response to a systemic immunization with *Lymphocytic Choriomeningitis virus (LCMV)*¹², E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$ donor cells primed *in vivo* with Lm-OVA via the oral route, also failed to generate detectable memory cells in the spleen or the intestine of WT recipient mice (Fig. 3b). In contrast, in another study by Chandele et al., using the same systemic LCMV immunization approach, E8 $_I^{-/-}$ CD8 $\alpha\beta$ T cells did generate systemic memory³⁰. However in that case, a drastic downregulation of CD8 $\alpha\beta$ was noticed during the initial priming phase, which was not seen on either WT CD8 $\alpha\beta$ T cells or the LCMV primed E8 $_I^{-/-}$ CD8 T cells in our published study¹². It is possible that stronger activation conditions in the Chandele study might have caused the downregulation of CD8 $\alpha\beta$, which likely resulted in similar effects on survival as mediated by activation-induced CD8 $\alpha\alpha$ on normal WT CD8 $\alpha\beta$ T cells. To test this, we analyzed the memory response of E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$ T cells primed systemically with Lm-OVA introduced intravenously (i.v.), which induces a much more potent immune response as compared to the oral route⁸. In contrast to the oral immunization, systemic priming of the E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$ T cells with Lm-OVA resulted in a clear memory response in the spleen and in the intestine comparable to that of WT OT-I cells (Fig. 3c). Furthermore, similar to the Chandele study³⁰, a drastic downregulation of CD8 $\alpha\beta$ was noticed during the potent priming of E8 $_I^{-/-}$ OT-I CD8 $\alpha\beta$ T cells

activated via the i.v. route, whereas, such downregulation was not observed when $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ T cells were primed via the oral route (**Fig. 3d**). Although the activation-induced downregulation of $CD8\alpha\beta$ could explain the survival of the $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ T cells during the systemic priming, it does not explain the longterm survival of these cells in the intestine where TL is constitutively expressed on the IEC. To further investigate this, we analyzed the $CD8\alpha\beta$ expression of the $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ memory T cell subsets in the spleen and the intestine. Interestingly, whereas $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ memory cells in the periphery expressed normal levels of $CD8\alpha\beta$, memory $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ IEL that persist in the presence of TL expressed much reduced levels of $CD8\alpha\beta$ (**Fig. 3e**). These results indicate that the mechanism of TICD continuously and selectively shapes the repertoire of the memory cells that accumulate at the mucosal site of the intestine. In support of this, in the absence of TL expression in the intestine of $TL^{-/-}$ hosts, similar to the systemic priming, there was no difference in the efficiency of memory formation in the spleen or the intestine when WT OT-I or $E81^{-/-}$ OT-I $CD8\alpha\beta^{+}$ T cells were primed via the oral route (**Fig. 3f**). Furthermore, there was also no selective accumulation of $CD8\alpha\alpha$ expressing WT OT-I $CD8\alpha\beta^{+}$ IEL in the $TL^{-/-}$ hosts, indicating that TL on the epithelial cells in the intestine imposes a selective pressure to promote the local accumulation of $CD8\alpha\alpha$ -expressing effector memory T cells (**Fig. 3g**). These results indicate that the requirement for activation-induced $CD8\alpha\alpha$ on primary effector cells is in part determined by the presence of TL. The data are consistent with a role for activation-induced $CD8\alpha\alpha$ in sequestering TL ligand away from the $CD8\alpha\beta$ co-receptor, thereby avoiding TICD of the $CD8\alpha\beta^{+}$ primary effector T cells.

CD8 $\alpha\alpha$ expression is linked to the intensity of TCR activation.

Due to the relatively high affinity interaction of CD8 $\alpha\alpha$ with TL, activation-induced expression of CD8 $\alpha\alpha$ can be distinguished from CD8 $\alpha\beta$ co-receptor expression using TL tetramers¹². Activated CD8 $\alpha\beta$ T cells do not all induce CD8 $\alpha\alpha$ to the same extent, and using TL tetramers a variegated expression pattern of high (CD8 $\alpha\alpha^{\text{hi}}$) and low (CD8 $\alpha\alpha^{\text{lo/-}}$) expression is typically observed. Together with the fact that the initial induction of CD8 $\alpha\alpha$ requires TCR stimulation, this suggests that there might be a close link between the intensity of TCR activation and the degree of CD8 $\alpha\alpha$ induction. In support of this, TL tetramer staining of polyclonal CD8 $\alpha\beta^+$ WT T lymphocytes activated *in vitro* with variable concentrations of soluble α -CD3 and α -CD28 antibodies showed graded increase in CD8 $\alpha\alpha$ expression with higher concentrations of α -CD3/CD28 mAbs (**Fig. 4a**). Furthermore, OT-I T cells stimulated with different altered peptide ligands (APL) that bind equally well to the K^b class I molecule as the original OT-I ligand, SIINFEKL (N4), but which have different antigenic potencies³¹, also showed a tight association between the level of CD8 $\alpha\alpha$ induction and the degree of TCR activation. Therefore the high affinity N4 ligand induced the highest amounts of CD8 $\alpha\alpha$ expression compared to the lower-affinity altered peptide ligands (**Fig. 4b**). Similar results of affinity-based induction of CD8 $\alpha\alpha$ were obtained *in vivo* when mice were analyzed that were infected orally with Lm-OVA after they received either a high- or a low-precursor frequency of naïve donor OT-I cells, which because of antigenic competition will model a low or high antigen dose, respectively (**Fig. 4c**). Additionally, we analyzed recipient mice adoptively transferred with equal amounts of OT-I precursor cells, but orally infected with bacteria expressing either the low-affinity Q4 (Lm-Q4)- or the high-affinity N4 (Lm-N4)-antigen. Mice receiving higher affinity N4 as compared to Q4 antigen generated more CD8 $\alpha\alpha$ -expressing CD8 $\alpha\beta$ T cells (**Fig. 4d**). In each of these approaches, the results

consistently indicated that the level of CD8 $\alpha\alpha$ induction represents a sensitive measurement for the intensity of the signal strength received through the activated TCR.

Similar to activation-induced CD8 $\alpha\alpha$; IL-7 receptor (IL-7R α) expression also has been proposed as a marker for memory precursor cells³². However, in contrast to CD8 $\alpha\alpha$, IL-7R expression did not correlate with TCR activation, and instead, IL-7R was constitutively expressed on naïve cells and initially down regulated during activation at the time when CD8 $\alpha\alpha$ is first up regulated (**Supplementary Fig. 3a**). The reciprocal expression of CD8 $\alpha\alpha$ and IL-7R suggests different roles for these molecules in memory programming and/or survival. Consistent with this, a mutation in the cytoplasmic IL-7R α Y449XXM motif (IL-7R α ^{449F}), known to impair the long-term survival of IL-7R-dependent CD8 memory T cells³³, did not interfere with the induction of CD8 $\alpha\alpha$ or the survival and generation of OT-I/ IL-7R α ^{449F} memory T cells in response to an oral immunization with Lm-OVA (**Supplementary Fig. 3b**). These data indicate that the affinity-based selective programming of memory precursor cells does not depend on IL-7R signals.

Overall, the data indicate that in addition to being a memory precursor marker¹², CD8 $\alpha\alpha$ expression also reports on the affinity/avidity of the antigen signal received by activated CD8 $\alpha\beta$ primary effector cells. The affinity-based induction of CD8 $\alpha\alpha$, together with the ability of CD8 $\alpha\alpha$ to sequester TL and avoid TICD therefore represents a mechanism to selectively preserve the most avid CD8 $\alpha\beta$ primary effector cells as part of the memory precursor pool.

CD8 $\alpha\alpha$ expression marks high affinity CD8 $\alpha\beta$ T cells in humans.

Previous evidence indicated that the mouse TL tetramers also detect expression of human CD8 $\alpha\alpha$ homodimers^{12, 17}. Consistent with activation-induced expression of CD8 $\alpha\alpha$, human CD8 $\alpha\beta$ effector cells also stained with TL tetramers, whereas naïve T cells did not (**Fig. 5a**). TL

tetramer staining could be blocked with an anti-human CD8 α antibody, but not with an anti-CD8 β antibody, confirming the specificity of the TL tetramer for human CD8 $\alpha\alpha$ (**Fig. 5b** and **Supplementary Fig. 4**). Furthermore, the subset of immuno-dominant, high affinity, CMV-pp65-specific CD8 $\alpha\beta$ T cells³⁴, isolated from *Cytomegalovirus* (CMV)-sero-positive individuals, stained almost exclusively with TL tetramer, which could be blocked with anti-CD8 α (**Fig. 5c**), indicating that CD8 $\alpha\alpha$ expression on human CD8 $\alpha\beta$ effector T cells also is associated with high affinity effector cells.

Retinoic acid and TGF- β promote affinity-based accumulation of CD8 $\alpha\alpha$ ⁺CD8 $\alpha\beta$ T cells.

CD8 $\alpha\alpha$ -expressing CD8 $\alpha\beta$ T cells are highly enriched in the epithelium of the intestine, suggesting that a selective process based on CD8 $\alpha\alpha$ expression might drive this localized accumulation. Consistent with this, when primed *in vitro* CD8 $\alpha\alpha$ induction was stronger using mLN DC compared to spleen DC (**Fig. 6a,b**). In the presence of exogenous RA, normally released by mLN DC during priming²¹, spleen DC also mediated strong induction of CD8 $\alpha\alpha$ on the OT-I T cells they primed (**Fig. 6a,b**). Whereas a retinoic acid receptor (RAR) inhibitor reduced CD8 $\alpha\alpha$ expression on T cells primed by mLN DC (**Fig. 6a**). Likewise, TGF- β known to be an important modulator of mucosal T cell differentiation also increased CD8 $\alpha\alpha$ induction on activated CD8 $\alpha\beta$ primary effector cells (**Fig. 6c**). Both, RA- and TGF- β -mediated enhanced induction of CD8 $\alpha\alpha$ were observed, however, only under strong antigen activation conditions, suggesting that they influence CD8 effector differentiation by further promoting the selective marking of high affinity effector cells by CD8 $\alpha\alpha$ (**Fig. 6b, c**).

The constitutive and enhanced expression of TL on the mucosal migratory DC known to release RA and TGF- β (**Fig. 1e, f**), together with the increased CD8 $\alpha\alpha$ induction on high affinity effectors in the presence of RA as well as TGF- β , indicate that the selective rescue of high affinity memory precursor cells is geared toward effector cells that home to the gut. In agreement with this, CD8 $\alpha\alpha$ -expressing OT-I cells were first detectable at mucosal induction sites, such as the mLN and Peyer's patches, early after oral antigen exposure (**Fig. 6d**) and gradually accumulated during the contraction and memory phase within the pool of $\alpha_E\beta_7$ integrin (CD103⁺) T_{EM} in the gut epithelium, but not in the CD103⁻ memory cells that persist systemically (**Fig. 6e**).

Constitutive TL on epithelial cells continues to select mature CD8 $\alpha\beta$ T_{EM}.

The constitutive TL expression on intestinal epithelial cells^{15, 16}, suggests that TL might continuously shape the resident mucosal memory CD8 $\alpha\beta$ ⁺ T cell population even after rechallenge. To investigate this, we examined the fate of primary and secondary CD8 $\alpha\alpha$ ^{hi}- or CD8 $\alpha\alpha$ ^{lo/-}-CD8 $\alpha\beta$ ⁺ effector T cells *in vivo*. OT-I cells initially primed *in vitro* in the absence of TL, using TL negative APC, were sorted into CD8 $\alpha\alpha$ ^{hi}- and CD8 $\alpha\alpha$ ^{lo/-}-primary effector T cells and adoptively transferred to WT recipient mice. Both subsets of primary effector cells displayed a similar short term homing capacity (**Supplementary Fig. 5a**), and both effector T cell types responded alike when tested *in vitro* for IFN γ production (**Supplementary Fig. 5b**) or *in vivo* for cytotoxicity (**Supplementary Fig. 5c**). However, in response to an oral re-challenge with Lm-OVA, primary memory OT-I T cells derived from the CD8 $\alpha\alpha$ ^{hi} precursors expanded in the spleen and in the intestine of the WT recipient mice, whereas memory cells from the CD8 $\alpha\alpha$ ^{lo/-} effector pool were only detectable in the host spleen, but not in the intestine (**Fig. 7a**). These data indicate that only CD8 $\alpha\alpha$ ^{hi} primary memory cells can persist long-term as mucosal T_{EM} in proximity of TL

constitutively expressed on the epithelial cells. Upon re-challenge, activated memory cells in lymphoid tissues expand and migrate as secondary effector cells to non-lymphoid tissues, such as the epithelium of the gut³⁵. In agreement with this, comparable numbers of effector cells derived from either CD8 α^{hi} or CD8 $\alpha^{\text{lo/-}}$ primary effector OT-I cells were present in the intestine 5 days after recall (**Fig. 7b**). Nevertheless, when analyzed 45 days later, progeny of CD8 α^{hi} effector cells were present as secondary memory cells in both the spleen and the intestine, whereas the CD8 $\alpha^{\text{lo/-}}$ secondary effector cells did not remain as secondary T_{EM} in the intestine (**Fig. 7c**). In contrast, *in vitro* primed CD8 $\alpha^{\text{lo/-}}$ CD8 β^+ OT-I effector cells accumulated efficiently as T_{EM} within the gut epithelium of TL^{-/-} recipient mice (**Fig. 7d**), indicating that the constitutive expression of TL continues to mediate selective pressure that prevents the accumulation of CD8 $\alpha^{\text{lo/-}}$ primary and secondary effector cells as mucosal T_{EM}. These results also specify that CD8 $\alpha^{\text{lo/-}}$ effector cells are not intrinsically incapable of converting to mucosal T_{EM}, but that under normal physiological conditions, only CD8 α^{hi} primary effector cells form long-lived mucosal T_{EM} in proximity to TL constitutively expressed on the epithelial cells.

Constitutive TL mediates affinity maturation of mucosal memory CD8 $\alpha\beta$ T cells.

A recent study, using low-affinity APL for *in vivo* priming, suggested that affinity maturation of memory T cells was the result of enhanced expansion and delayed contraction of the high affinity responding effector cells³¹. Our results here suggest that, in addition, the TL-mediated selective survival of CD8 α -expressing high affinity memory cells might also contribute to ensure affinity maturation of memory populations at the mucosal border. To provide direct evidence for this, we used the same APL approach³¹ to examine memory generation *in vivo* in the presence or absence of TL. Naïve OT-I cells were adoptively transferred to either WT or TL^{-/-} recipient mice

that were subsequently orally infected with bacteria expressing the low affinity APL, Q4 (Lm-Q4), which does not effectively induce CD8 α on primed OT-I effector cells (**Fig. 4d**). Fewer OT-I effector cells were detectable in the blood of WT mice compared to TL^{-/-} animals when analyzed 7 days after oral immunization with Lm-Q4 (**Fig. 7e**), suggesting that TL induced on the priming mucosal APC controls in part the expansion of the primary effector pool. In the intestine, where TL is constitutively expressed by the IEC, the selective impact of TL was even more pronounced and OT-I memory IEL generated in response to the low affinity peptide Q4 are barely detectable in WT animals whereas they were readily present in the TL^{-/-} mice (**Fig. 7f**). These results indicate that the continuous expression of TL on the epithelium of the intestine selectively eliminates low affinity cells from the pool of mature mucosal T_{EM}. Together with the increase in mucosal memory in the TL^{-/-} mice, also the systemic memory pool was increased (**Fig. 7f**), suggesting that in addition to the TL-mediated affinity selection of mature memory cells in the intestine, TL induced on the mucosal APC during priming might already provide a first affinity- selection step by eliminating low affinity/avidity primary effector cells from the memory precursor pool. To further test this, we immunized WT or TL^{-/-} recipient mice with Lm-Q4 via the i.v. route. Under these conditions, TL expression during priming had only a minimal effect on the effector- or memory phase of peripheral T cells, which was comparable between the TL^{-/-} and WT recipient mice (**Figs. 7g and 7h**). In sharp contrast however, the accumulation of T_{EM} at the mucosal site, where TL is constitutively expressed, remained under the TL selective pressure (**Fig. 7h**). These results indicated that T cells primed at the mucosal priming site undergo an initial selection step mediated by TL induced on the migratory DC, whereas the constitutive expression of TL on the mucosal epithelium provides for additional and constant selection pressure that drives continuous affinity

maturation of the mature memory pool that accumulates longterm at the mucosal interface of the intestine.

To evaluate the importance of pre-existing TL-CD8 α -selected mucosal memory T cells residing at this entry port, we examined the resistance against an oral infection with Lm in mice with or without affinity-selected memory cells. To this end, mice transferred with either WT or E8 $_I^{-/-}$ OT-I cells were orally immunized with an attenuated strain of Lm-OVA (ActA $^-$ Lm-OVA) (10^9 cfu). The mice were subsequently re-challenged orally with a higher dose (10^{10} cfu) of WT Lm-OVA and analyzed for systemic spreading of the pathogen. In contrast to the efficient resistance observed in mice which received the WT OT-I precursor cells, which generated memory cells in the intestine and elsewhere, pre-immunized mice that initially received the E8 $_I^{-/-}$ OT-I precursor cells failed to generate affinity selected memory and they showed significantly less resistance to prevent systemic spreading of the orally introduced pathogen (**Fig. 7i**). These results underscore the importance of the selective immune memory differentiation process as a critical mechanism for the efficient generation of pre-existing immunity at critical mucosal interfaces that form the main entry sites for invading pathogens.

DISCUSSION

The data presented here define a fundamentally new concept for our understanding of immune memory differentiation and in particular mucosal immunity. The data demonstrate that an affinity-based selective process operates *in vivo* that preserves the optimal effector cells to become long-lived memory T cells that form pre-existing and heightened protective immunity. This mechanism is especially geared to generate high affinity T $_{EM}$ that line the mucosal barrier of the intestine, where most pathogens enter the body.

The results also demonstrate a functional role TL, a non-classical MHC class I-like molecule, in mediating TICD of CD8 $\alpha\beta$ effector T cells that fail to induce CD8 $\alpha\alpha$. Because TL is a much stronger ligand for CD8 $\alpha\alpha$ as compared to CD8 $\alpha\beta$, CD8 $\alpha\alpha$ likely can sequester TL away from CD8 $\alpha\beta$ and prevent TICD (**Supplementary Fig. 6**). The induction of CD8 $\alpha\alpha$ is directly linked to the degree of TCR signal strength, which leads to the selective survival of the most avid effector cells to become memory T cells. The constitutive expression of TL on the epithelial cells in the intestine continues selective pressure which mediates affinity maturation of the mucosal T_{EM} population in response to repeated re-challenges (**Supplementary Fig. 6**).

The data here, using the Lm model are consistent with our previously published study using the LCMV model system, which also indicated a critical role for activation-induced CD8 $\alpha\alpha$ in the generation of CD8 $\alpha\beta$ memory T cells. Nevertheless, two subsequent studies challenged this conclusion and provided evidence that under certain conditions CD8 $\alpha\beta$ ⁺ E8_I^{-/-} memory T cells could also be generated in a CD8 $\alpha\alpha$ -independent fashion^{30, 36}. In those two studies however and similar to what we observed here using Lm immunizations via the iv route, there was a pronounced down regulation of CD8 $\alpha\beta$ expression during the priming of the E8_I^{-/-} CD8 $\alpha\beta$ T cells, which was not observed in our previous study using the LCMV system or during oral immunizations using the Lm system as shown here. The fact that in the absence of CD8 $\alpha\beta$ downregulation in both of those cases, E8_I^{-/-} CD8 $\alpha\beta$ T cells failed to accumulate as memory cells, indicates that strong activation signals which result in down regulation of CD8 $\alpha\beta$ co-receptor on the E8_I^{-/-} mutant cells may rescue CD8 $\alpha\beta$ memory precursor cells similarly to the biological activity of activation-induced CD8 $\alpha\alpha$ on normal WT CD8 $\alpha\beta$ effector cells.

Although, a sequence-based homologue for TL in humans has not been identified, TL and the non-classical MHC class I molecule, HLA-G, display striking similarities, including their

restricted pattern of expression, the limited antigen presentation capacity, the relative strong affinity for CD8 $\alpha\alpha$ compared to CD8 $\alpha\beta$ and the ability to induce Fas-FasL cell death of activated CD8 $\alpha\beta$ T cells^{25, 37, 38}. These parallels suggest that, similar to other non-classical MHC/HLA pairs, TL and HLA-G might represent functional homologues of each other, and they further suggest that an affinity-based selective memory differentiation program likely operates in humans as well. Consistent with this, we showed that activated but not naïve human CD8 $\alpha\beta$ T cells co-express CD8 $\alpha\alpha$, and CD8 $\alpha\alpha$ expression also coincided with the high affinity CMVpp65-specific CD8 $\alpha\beta$ effector T cells. In addition, a recent study indicated that the endogenous protective immune response against HIV was characterized by a CD8 $\alpha\alpha$ -expressing CD8 $\alpha\beta$ subpopulation that exhibited strong antiviral activity³⁹ and high-avidity HIV-specific CD8⁺ T cell clonotypes were largely preserved in patients who control viremia, but not in progressive chronic HIV infections. All together, these observations suggest that CD8 $\alpha\alpha$ induction on human CD8 $\alpha\beta$ T cells is also an activation-induced and affinity-based process that marks the avid effector cells.

Most infections, including Lm but also many viral infections such as HIV and SIV infections, are acquired across mucosal barriers, and several studies have demonstrated that CD8⁺ CTL responses play a crucial role in the initial containment and early control of pathogen replication⁴⁰⁻⁴⁴. Although such responses may be unable to provide sterilizing protection, they can control the pathogen load and delay or even prevent spreading and onset of disease, as well as reduce the potential for secondary transmission. Therefore, the finding that an endogenous TCR quality-based mechanism may select for the most avid effector cells to form immune memory cells that have the capacity to reside longterm at mucosal interfaces, has significant implications for the design of new and improved strategies to induce effective pre-existing protective immunity, not only systemically but also locally at the major and most vulnerable entry sites for pathogens.

METHODS

Mice. C57BL/6 CD45.2 (Ly5.2), referred to as WT, and CD45.1 (B6.SJL, Ly5.1) congenic, B6.MRL-*Fas*^{lpr}/J and B6.Smn.C3-*FasL*^{gld}/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). OT-I TCR-transgenic mice were crossed onto the Ly5.1 congenic background. Additionally, *E81*^{-/-}, *IL-7Rα*^{449F}, and TL-Tg mice were crossed to OT-I mice. TL-Tg mice were generated by forced expression of the *T18^d* gene under the *D^d* promoter and backcrossed to the C57BL/6 background for more than 12 generations. *TL*^{-/-} mice were generated by deletion of the *T3^b* gene in the C57BL/6 background. Mice were maintained by breeding under specific pathogen-free conditions in the animal facility of the La Jolla Institute for Allergy & Immunology. Unless otherwise noted, mice were maintained under specific pathogen-free conditions. Sentinel mice from the *RAG1*^{-/-} colony were tested to be negative for *Helicobacter spp.* and *Citrobacter rodentium*. Animal care and experimentation were consistent with the NIH guidelines and were approved by the Institutional Animal Care and Use Committee of the La Jolla Institute for Allergy and Immunology.

T cell isolation, cell sorting, CFSE labeling and adoptive transfer. CD8⁺ OT-I cells were purified by magnetic negative selection using the MACS CD8α⁺ T cell isolation kit according to the manufacturer's protocol (Miltenyi Biotec). CD44^{low} cells were sorted as naïve CD8 OT-I cells by FACSaria (Becton Dickinson). In some cases, sorted cells were CFSE-labeled. OT-I cells were resuspended at a concentration of 10 × 10⁶ cells/ml in PBS and CFSE was added to a final concentration of 5 μM (Invitrogen). After 10 min of incubation at 37°C, labeling was quenched

with ice-cold DMEM medium with 10% FCS. Cells were washed with PBS three times and intravenously injected into the recipient mice.

DC isolation and activation. Pooled spleens or MLNs were cut into small pieces and digested with collagenase D (Roche) at room temperature for 30 min and EDTA (5 mM in final concentration) was added for the last 5 min. Digested tissues were further homogenized and then enriched for CD11c⁺ DC by positive selection using a MACS cell separation (Miltenyi Biotec). For DC activation *in vitro*, freshly isolated spleen DC were cultured with 1 mM CpG DNA (1826, IDT) for 1 day and analyzed for TL expression by using anti-TL antibody (HD168).

***In vitro* T cell stimulation culture.** For total splenocyte culture, 5×10^5 total splenocytes were cultured in 96-well plates in the presence of anti-CD3 and anti-CD28 antibodies. For artificial APC/OT-I cultures, either the transfected adherent fibroblast cell line (MEC.B7) expressing the costimulatory molecule B7.1, or the OVA-expressing cell line (APC, MEC.B7.SigOVA) having the OVA-derived, H-2K^b-restricted peptide epitope OVA₂₅₇₋₂₆₄ (SIINFEKL), along with B7.1, were used. Irradiated APCs were cultured at 150,000 cells per well in 24-well plates overnight to establish a single layer. Naïve OT-I cells (5×10^5) were added to the monolayer of APCs in 2 ml of medium. The TL expressing APC (APC-TL) were generated by transfection of MEC.B7.SigOVA cells with a plasmid expressing *T18^d* gene. TL expression was confirmed by staining with a TL-specific antibody (HD168). For DC/OT-I culture, purified DC were incubated with 1 nM SIINFEKL for 2 h and then washed. 2×10^5 CFSE-labeled naïve OT-I cells were cultured with 4×10^4 peptide-pulsed DC, with or without 100 nM all-trans RA (Sigma), in 96-well plates for 3-4 d. RA receptor antagonist LE135 (TOCRIS bioscience) was used for some cultures.

Bone marrow-derived DC immunization. Bone marrow was flushed from the tibia and femurs of 8-10-week-old mice and red blood cells were lysed. Bone marrow cells were plated at 5×10^5 cells/ml in complete IMDM with 20 ng/ml rmGM-CSF (Kyowa-Hakko Kirin California). Fresh media containing rmGM-CSF were added on day 3 and half of the media was gently replaced on day 6. 100 ng/ml LPS (Sigma) was added on day 6 for 1 d to induce DC maturation and then 1 mM SIINFEKL was added to the culture 2 h before collecting cells. After extensive washing, 5×10^5 DC were injected *i.v.* in mice, which had previously received naïve OT-I cells 1 d earlier.

qRT-PCR. RNA from the FACS-sorted DC were extracted with TRIZol (Invitrogen) and complementary DNA (cDNA) were synthesized using the iScript cDNA Synthesis kit (Bio-Rad). Real time RT-PCR was performed with the Roche 480 real-time PCR System. Values were normalized by the amount of L32 in each sample. The primers for qPCR are as following: TL-forward 5'-TGT ATG GCT GTG AGG TGG AG-3', TL-reverse 5'-GCT CCC ACT TGC TTC TGG T-3'; L32-forward 5'-GAA ACT GGC GGA AAC CCA-3', L32-reverse 5'-GGA TCT GGC CCT TGA ACC TT-3'.

Bacterial infection and bacterial counts in organs. ActA⁻ Lm-OVA for immunization were prepared from cultures in brain heart infusion broth. Lm-N4OVA and Lm-Q4OVA strains stably express chicken ovalbumin (AA₁₃₄₋₃₈₇) containing either the native ligand SIINFEKL₂₅₇₋₂₆₄ (N4) or the altered peptide ligand SIIQFEKL (Q4). Bacteria were washed and resuspended in Hanks' balanced salt solution (HBSS) prior to oral infection by gavage. Bacterial injection stocks were plated to confirm the CFU. To count the bacteria in organs, livers were sterilely dissected,

homogenized and lysed with 0.1% Triton X-100. Serial dilutions were plated onto BHI plates and bacterial colonies were counted 24 h after incubation at 37 °C.

IEL preparation. In brief, small intestines were removed and separated from Peyer's patches. They were cut longitudinally and then into 0.5 cm pieces. The pieces were shaken for 40 min in Mg²⁺-free, Ca²⁺-free HBSS supplemented with 1 mM dithiothreitol and 5% FCS. Cells were collected from the washes and passed over a discontinuous 40/70% Percoll (Pharmacia Biotech) gradient at 900 g for 20 min. IEL were then isolated from the Percoll-gradient interface and washed free of Percoll.

Immunofluorescence staining and flow cytometry. For mouse samples, a standard surface staining protocol included pre-incubated with anti-CD16/CD32 Fc-receptor antibody (2.4G2) to block Fc-antibody binding. Then, cells were stained in cold PBS containing 0.5% FBS and 0.05% sodium azide with the relevant labeled antibodies and tetramers. The following antibodies were used: CD8 α (clone 53.6.7), CD8 β (clone 53-5.8), CD44 (clone IM7), CD45.1 (clone A20), CD45.2 (clone 104), CD103 (clone M290), CD127 (IL-7R α , clone A7R34), and IFN- γ (clone XMG1. 2). All primary antibodies were directly conjugated to fluorophores (BD Biosciences or eBioscience). CD8 α was detected with PE-labeled TL-tetramers. OVA-specific CD8 T cells were detected with PE-labeled K^b/ OVA₂₅₇₋₂₆₄ tetramers. For intracellular staining of IFN γ , splenocytes or IEL were stimulated with OVA₂₅₇₋₂₆₄ (5 μ g/ml) for 5 h in the presence of brefeldin A at 37°C. After surface staining, intracellular cytokine staining for IFN γ was performed using a Cytotfix/Cytoperm Kit (BD Biosciences), according to the manufacturer's directions. For detection of cell apoptosis and death, cells were stained with Annexin V-APC (BD Biosciences) using the

manufacturer's protocol and cells were analyzed immediately after staining. For human samples, peripheral blood samples were obtained from healthy volunteers (26-78 years old). Informed written consent was obtained from all participants and the blood collection was approved by the ethics committee of the Innsbruck Medical University. Isolation of peripheral blood mononuclear cells (PBMC) was performed by density gradient centrifugation using Ficoll-Hypaque (Amersham Biosciences). Immunofluorescence surface staining of PBMC was performed using the following conjugated antibodies: TCR $\alpha\beta$ (FITC), CD3 (PerCP or APC-Cy7), CD4 (PerCP), CD8 α (PerCP), CD8 β (PE or APC), CD16 (FITC), CD28 (APC or PE-Cy7), CD45RA (FITC) and CD45RO (FITC) (BD Biosciences), CMVpp65₄₉₅₋₅₀₃ pentamer (PE or APC; ProImmune) and TL tetramer (PE). PBMC were pre-incubated with unlabeled anti-CD8 α (clone SK1; 2.5 $\mu\text{g}/\text{mL}$; BD Biosciences) or anti-CD8 β (polyclonal; 100 $\mu\text{g}/\text{mL}$; Abcam or clone 2ST8.5H7; 25 $\mu\text{g}/\text{mL}$; BD Biosciences) for 15 min at room temperature. After a washing step with PBS, TL tetramer (1:100) was incubated for 10 min at room temperature. Thereafter, PBMC were co-stained with the relevant antibodies for 30 min at 4-8°C. Plasma CMV IgG titers were analyzed by ELISA using Enzygnost[®] (Dade Behring). All the stained cells were analyzed on a FACSCalibur or FACSCanto II[®] flow cytometer (Becton Dickinson) and FlowJo software (Three Star) or FACSDiva[®] Software (BD Biosciences).

In vivo cytotoxicity assays. *In vivo* cytolytic activity was determined using B6 splenocytes differentially labeled with CFSE. The cells highly labeled (CFSE^{high}) were used as target cells and pulsed with OVA₂₅₇₋₂₆₄ (0.5 $\mu\text{g}/\text{ml}$; 90 min at 37°C, 5% CO₂), whereas CFSE^{low} labeled cells were pulsed with a negative control peptide, TRP-2₁₈₀₋₁₈₈ (0.5 $\mu\text{g}/\text{ml}$). Peptide-pulsed target cells were extensively washed to remove free peptide and then co-injected intravenously in a 1:1 ratio to

recipient mice. Sixteen hours later, spleens were removed and the ratio of CFSE^{low}/CFSE^{high} cells was determined by flow cytometry.

Acknowledgements. We wish to thank Dr. Michael Bevan for providing the Lm-OVA (N4 and Q4) reagents, M. Cheroutre for her contribution and Drs L. Qiao, X.Z. Wang, and the members of the Cheroutre and Kronenberg laboratories for helpful discussions and technical assistance. Dr. D. Littman (New York University School of Medicine, New York, NY) for providing the E8_T^{-/-} mice. This work was supported by NIH RO1 grants: AI064584 and AI050265 (H.C.), AG10152 (M.K., H.C.) and by pilot projects from the Vanderbilt University Digestive Disease Research Center and the Vanderbilt-Meharry Center for AIDS Research (L.V.K), NIH training grant CA009385 (D.O.-V). The human project was supported by the Austrian Science Fund (Project S9308-B05 to B.G.-L.). D.H.-B. is supported by a European FLARE fellowship funded by the Austrian Federal Ministry of Science and Research.

Description of the individual contribution made by each author. Y.H. and Y.P. provided input into the conceptual development and execution of the studies, as well as preparation of the manuscript. Y.W.Z., A.L., R.A. and I.B. provided technical assistance and input into data analyses. D.O.-V. and L.V.K. contributed to generation of TL-deficient mice. M.A.T. contributed to the generation and backcrossing of TL-Tg mice. D.H.B. and B.G.-L. performed human sample experiments. N.A. provided IL-7R α ^{449F} mice. S.P.S. helped with *in vitro* culture experiments. M.K. participated in discussions of the data and the preparation of the manuscript. H.C. conceived the ideas, generated the TL transgenic mice with assistance of M.A.T., wrote the manuscript and supervised the experiments.

Competing Interests statement. The authors declare no competing financial interests.

Correspondence and requests for materials should be addressed to H.C. (e-mail: hilde@liai.org)

1. Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. *Immunity* **33**, 451-463 (2010).
2. Cheroutre, H. & Madakamutil, L. Mucosal effector memory T cells: the other side of the coin. *Cell Mol Life Sci* **62**, 2853-2866 (2005).
3. Masopust, D., Vezys, V., Marzo, A.L. & Lefrancois, L. Preferential localization of effector memory cells in nonlymphoid tissue. *Science* **291**, 2413-2417 (2001).
4. Masopust, D., Vezys, V., Wherry, E.J., Barber, D.L. & Ahmed, R. Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population. *J Immunol* **176**, 2079-2083 (2006).
5. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* **401**, 708-712 (1999).
6. Wherry, E.J. *et al.* Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nat Immunol* **4**, 225-234 (2003).
7. Hansen, S.G. *et al.* Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. *Nat Med* **15**, 293-299 (2009).
8. Pamer, E.G. Immune responses to *Listeria monocytogenes*. *Nature reviews. Immunology* **4**, 812-823 (2004).
9. Mengaud, J., Ohayon, H., Gounon, P., Mege, R.M. & Cossart, P. E-cadherin is the receptor for internalin, a surface protein required for entry of *L. monocytogenes* into epithelial cells. *Cell* **84**, 923-932 (1996).
10. Bahjat, K.S. *et al.* Cytosolic entry controls CD8⁺-T-cell potency during bacterial infection. *Infect Immun* **74**, 6387-6397 (2006).
11. Starks, H. *et al.* *Listeria monocytogenes* as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. *Journal of immunology* **173**, 420-427 (2004).
12. Madakamutil, L.T. *et al.* CD8 α -mediated survival and differentiation of CD8 memory T cell precursors. *Science* **304**, 590-593 (2004).
13. Cheroutre, H. Starting at the beginning: new perspectives on the biology of mucosal T cells. *Annu Rev Immunol* **22**, 217-246 (2004).
14. Leishman, A.J. *et al.* T cell responses modulated through interaction between CD8 α and the nonclassical MHC class I molecule, TL. *Science* **294**, 1936-1939 (2001).
15. Hershberg, R. *et al.* Expression of the thymus leukemia antigen in mouse intestinal epithelium. *Proc Natl Acad Sci U S A* **87**, 9727-9731 (1990).
16. Wu, M., van Kaer, L., Itohara, S. & Tonegawa, S. Highly restricted expression of the thymus leukemia antigens on intestinal epithelial cells. *J Exp Med* **174**, 213-218 (1991).
17. Attinger, A. *et al.* Molecular basis for the high affinity interaction between the thymic leukemia antigen and the CD8 α molecule. *J Immunol* **174**, 3501-3507 (2005).
18. Olivares-Villagomez, D. *et al.* Thymus leukemia antigen controls intraepithelial lymphocyte function and inflammatory bowel disease. *Proc Natl Acad Sci U S A* **105**, 17931-17936 (2008).
19. Williams, M.A. & Bevan, M.J. Cutting edge: a single MHC class Ia is sufficient for CD8 memory T cell differentiation. *J Immunol* **175**, 2066-2069 (2005).

20. Eghtesady, P. *et al.* Expression of mouse Tla region class I genes in tissues enriched for gamma delta cells. *Immunogenetics* **36**, 377-388 (1992).
21. Iwata, M. *et al.* Retinoic acid imprints gut-homing specificity on T cells. *Immunity* **21**, 527-538 (2004).
22. Liu, Y. *et al.* The crystal structure of a TL/CD8alphaalpha complex at 2.1 A resolution: implications for modulation of T cell activation and memory. *Immunity* **18**, 205-215 (2003).
23. Contini, P. *et al.* Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. *J Immunol* **175**, 7244-7254 (2005).
24. Contini, P. *et al.* Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. *Eur J Immunol* **33**, 125-134 (2003).
25. Fournel, S. *et al.* Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. *J Immunol* **164**, 6100-6104 (2000).
26. Puppo, F. *et al.* Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. *Int Immunol* **12**, 195-203 (2000).
27. Arcaro, A. *et al.* CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. *J Exp Med* **194**, 1485-1495 (2001).
28. Cheroutre, H. & Lambolez, F. Doubting the TCR coreceptor function of CD8alphaalpha. *Immunity* **28**, 149-159 (2008).
29. Ellmeier, W., Sunshine, M.J., Losos, K., Hatam, F. & Littman, D.R. An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells. *Immunity* **7**, 537-547 (1997).
30. Chandele, A. & Kaech, S.M. Cutting edge: memory CD8 T cell maturation occurs independently of CD8alphaalpha. *J Immunol* **175**, 5619-5623 (2005).
31. Zehn, D., Lee, S.Y. & Bevan, M.J. Complete but curtailed T-cell response to very low-affinity antigen. *Nature* **458**, 211-214 (2009).
32. Kaech, S.M. *et al.* Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. *Nat Immunol* **4**, 1191-1198 (2003).
33. Osborne, L.C. *et al.* Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice. *J Exp Med* **204**, 619-631 (2007).
34. Trautmann, L. *et al.* Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. *J Immunol* **175**, 6123-6132 (2005).
35. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol* **22**, 745-763 (2004).
36. Zhong, W. & Reinherz, E.L. CD8 alpha alpha homodimer expression and role in CD8 T cell memory generation during influenza virus A infection in mice. *Eur J Immunol* **35**, 3103-3110 (2005).
37. Le Bouteiller, P. & Solier, C. Is antigen presentation the primary function of HLA-G? *Microbes Infect* **3**, 323-332 (2001).

38. Sargent, I.L. Does 'soluble' HLA-G really exist? Another twist to the tale. *Mol Hum Reprod* **11**, 695-698 (2005).
39. Boulassel, M.R., Mercier, F., Gilmore, N. & Routy, J.P. Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects. *Clin Immunol* **124**, 149-157 (2007).
40. Belyakov, I.M., Isakov, D., Zhu, Q., Dzutsev, A. & Berzofsky, J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. *J Immunol* **178**, 7211-7221 (2007).
41. Belyakov, I.M. *et al.* Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. *Blood* **107**, 3258-3264 (2006).
42. Daucher, M. *et al.* Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. *J Virol* **82**, 4102-4114 (2008).
43. Letvin, N.L. & Walker, B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. *Nat Med* **9**, 861-866 (2003).
44. Vogel, T.U. *et al.* Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. *J Virol* **77**, 13348-13360 (2003).

FIGURE LEGENDS

Figure 1: TL negatively affects memory generation of CD8 $\alpha\beta$ ⁺ T cells. (a) WT or TL^{-/-} mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. 30 days p.i., splenocytes (SPL) and IEL were isolated for IFN- γ intracellular staining after *ex vivo* re-stimulation with OVA₂₅₇₋₂₆₄ peptide. Graph depicts pooled data \pm s.e.m.. (b) 5×10^4 naïve Ly5.1⁺ CD8⁺ OT-I cells were adoptively transferred into WT or TL^{-/-} recipients. One day after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. Donor OT-I cells were tracked in the spleen and IEL 2 months p.i. Graph depicts pooled data \pm s.e.m.. (c) 1×10^6 naïve Ly5.1⁺ OT-I cells were transferred into WT or TL-Tg recipients. One day after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. The donor OT-I cells in the spleens and IEL were tracked two months p.i. Graph depicts pooled data \pm s.e.m.. (d) 5×10^4 Ly5.1⁺ naïve OT-I cells were transferred into C57BL/6 mice which were subsequently immunized i.v. with 5×10^5 OVAp-loaded DCs generated from bone marrow cells (BMDC) of WT or TL-Tg mice (top). Alternatively, OT-I cells were primed *in vitro* with TL negative APC or APC transfected with TL and then transferred to B6 recipients (bottom). Memory OT-I cells in the spleen were analyzed 2 months after DC immunization or after transfer of *in vitro* activated OT-I cells. Graph depicts pooled data \pm s.e.m.. (e) Migratory mLN DCs express a high level of TL. Spleen or mLN DC were sorted based on the CD11c and MHC II expression and assessed for TL expression by flow cytometry. Data are representative from three independent experiments. (f) Freshly isolated SPL or mLN DC were activated with CpG for 1 d and then analyzed for TL expression. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (unpaired *t*-test).

Figure 2: TL mediates death of activated CD8 $\alpha\beta$ ⁺ T cells. (a) 1×10^6 naïve Ly5.1⁺ OT-I cells were transferred into WT or TL-Tg recipients and the donor cells in the spleens were tracked one

month after transfer (top, $n = 5$ per group). 1×10^6 *in vitro* activated Ly5.1⁺ OT-I cells were transferred into WT or TL-Tg recipients and the donor cells in the spleen were tracked one month after transfer (bottom, $n = 8$ per group). (b) Naïve CD8 T cells sorted from WT, FasL^{gld} or FasL^{lpr} mice were stimulated *in vitro* by anti-CD3/-CD28 beads for 3 d. 0.5×10^6 activated CD8 T cells were transferred into Ly5.1⁺ WT or TL-Tg recipients and the donor cells in the spleens were tracked 1 month after transfer. Representative data are shown of four mice analyzed in each group. Two independent experiments were performed in each case.

Figure 3: Activation-induced CD8 $\alpha\alpha$ rescues CD8 $\alpha\beta$ primary effector T cells from TICD.

(a) 2×10^5 CFSE-labeled naïve E8₁^{-/-} OT-I cells were cultured with 4×10^4 OVA-pulsed DCs from SPL or mLN of WT or TL^{-/-} mice that were previously orally infected with ActA⁻ Lm-OVA. After 2 d culture, OT-I cells were harvested and analyzed for cell death by Annexin V staining. Data are representative of three independent experiments. (b) 5×10^4 naïve Ly5.2⁺ WT or Ly5.2⁺ E8₁^{-/-} OT-I cells were adoptively transferred into Ly5.1 recipient mice. 1 d after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. Donor OT-I cells were tracked in the spleen and IEL, 2 months p.i.. Graph depicts pooled data \pm s.e.m.. (c) 5×10^4 naïve Ly5.2⁺ WT or Ly5.2⁺ E8₁^{-/-} OT-I cells were adoptively transferred into Ly5.1 recipient mice. 1 d after transfer, mice were intravenously infected with 2.5×10^5 ActA⁻ Lm-OVA. Donor OT-I cells were tracked in the spleen and IEL, 2 months p.i.. Graph depicts pooled data \pm s.e.m.. (d) As described in (b) and (c), CD8 β expression was measured on effector WT OT-I or E8₁^{-/-} OT-I cells 7 days post oral infection (left panel) or i.v. infection (right panel). (e) As described in (c), CD8 β expression was measured on memory WT OT-I or E8₁^{-/-} OT-I cells 2 m post i.v. infection in the spleen and IEL (f, g) 5×10^4 naïve Ly5.1⁺Ly5.2⁺ WT OT-I and 5×10^4 naïve Ly5.2⁺ E8₁^{-/-} OT-I cells were co-transferred into

Ly5.1⁺ WT or Ly5.1⁺ TL^{-/-} mice. One day after transfer, the mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. Two months p.i., memory OT-I cells were tracked in the spleen and IEL. (f) Graph depicts pooled data \pm s.e.m. ($n = 5$ per group). (g) Staining for CD8 α expression, using TL-tetramers, on gated memory WT OT-I cells in IEL of WT or TL^{-/-} recipient mice 2m p.i. Representative of at least two independent experiments.

Figure 4: CD8 α expression correlates with the intensity of TCR activation. (a) Total splenocytes were cultured in the presence of graded concentration of soluble anti-CD3 and anti-CD28 antibodies. CD8 α expression, as measured by TL tetramer staining, was analyzed 3 d after *in vitro* culture. Representative data on gated CD8⁺ T cells are shown. Three independent experiments were performed. (b) Naïve OT-I cells were cultured with artificial APC (MEC.B7) in the presence of graded concentration of OVA₂₅₇₋₂₆₄ SIINFEKL (N4) or altered peptide ligands (Q4R7 and Q4). CD8 α expression was detected 2 d after *in vitro* culture. Three independent experiments were performed. (c) 100,000 or 1,000 sorted naïve Ly5.1⁺ CD8⁺ OT-I cells were transferred into B6 recipient mice. 1 d after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. 7 d p.i., CD8 α expression was analyzed on Ly5.1⁺ CD8⁺ OT-I cells from the spleen and IEL ($n = 4$ mice per group). (d) 5×10^4 naïve Ly5.1⁺ CD8⁺ OT-I cells were transferred into WT recipient mice. 1 d after transfer, mice were orally infected with 2×10^8 WT Lm-Q4OVA or Lm-N4OVA. 7 d p.i., CD8 α expression was analyzed on donor OT-I cells from the spleen and IEL ($n = 5$ mice per group).

Figure 5: CD8 α expression marks effector memory CD8 α β T cells in humans. (a) Expression of CD8 α on polyclonal human naïve (T_N; CCR7⁺CD45RA⁺), recently activated

effector-memory (T_{EMRA} ; $CCR7^-CD45RA^+$), effector-memory (T_{EM} ; $CCR7^-CD45RA^-$) and central-memory (T_{CM} ; $CCR7^+CD45RA^-$) $CD8^+$ T cells was measured by TL-tetramer staining. The numbers indicate the percentage of TL-tetramer^{hi} cells. Graph depicts pooled data \pm s.e.m. on percentage of $CD8\alpha\alpha$ expression on human $CD8^+$ T cells ($n = 9$). *** $P < 0.001$ (unpaired t -test). (b) TL-tetramer staining of human T_{EMRA} $CD8^+$ T cells is blocked by anti- $CD8\alpha$ but not anti- $CD8\beta$ antibody. Data are representative of two independent experiments. (c) CMV_{pp65} -specific $CD8^+$ T cells display a T_{EM}/T_{EMRA} phenotype and persist at high frequency in humans. Data from two representative donors from a total of six persons are shown. The TL-tetramer staining was absent on naive $CD8^+$ T cells and was blocked by an anti- $CD8\alpha$ antibody.

Figure 6: Retinoic acid promotes the affinity-based accumulation of $CD8\alpha\alpha^+CD8\alpha\beta$ T cells in the intestine. (a) OT-I cells were stimulated by OVA_p-loaded DCs from SPL or mLN of WT mice with or without 100 nM RA (dot plots) or with LE135 (histogram) *in vitro* for 3 d and $CD8\alpha\alpha$ expression was analyzed. Data are representative of five independent experiments. (b,c) OT-I cells were stimulated by SPL or mLN DCs pulsed with OVA_p (high, 1 nM; low, 0.01 nM) in the presence or absence of 100 nM RA (b) or 5 ng/ml TGF- β (c) *in vitro* for 3 d and $CD8\alpha\alpha$ expression was analyzed. Data are representative of more than five independent experiments. (d,e) 0.5×10^6 $CD8^+$ OT-I cells isolated from naïve $Ly5.1^+$ OT-I⁺ $Rag^{-/-}$ mice were adoptively transferred into B6 recipient mice. 1 d after transfer, mice were orally infected by 0.5×10^9 ActA⁻ Lm-OVA. $CD8\alpha\alpha$ expression was measured on gated donor OT-I cells from the SPL, mLN, PP and IEL, 5 d p.i. (d). $CD8\alpha\alpha$ and $CD103$ expression is shown on gated donor OT-I cells from the spleen and IEL on days 12, 21 and 75 p.i. (e). Representative data from two to three mice per group are shown. At least three independent experiments were performed.

Figure 7: Constitutive expression of TL on intestinal epithelial cells mediates selection of mature memory CD8 α β T cells. (a,b) Naïve Ly5.1⁺ CD8⁺OT-I cells were cultured in the presence of APC (MEC.B7.SigOVA). After 2 days' culture, CD8 α ^{hi} and CD8 α ^{lo/-} OT-I cells were sorted and cultured for 3 more days *in vitro*. Then 0.5×10^6 CD8 α ^{hi} or CD8 α ^{lo/-} cells were adoptively transferred into B6 recipients. One month after transfer, mice were orally infected with 5×10^8 ActA⁻ Lm-OVA. Donor Ly5.1⁺ OT-I cells were tracked in the spleen and IEL 3 d (a) and 5 d (b) p.i.. Representative data from 3-4 mice in each group are shown. At least five independent experiments were performed. (c) As shown in (a), secondary OT-I memory cells were assessed in the IEL 45 d p.i.. Representative data from three to four mice in each group are shown. At least three independent experiments were performed. (d) Sorted *in vitro* activated Ly5.1⁺ CD8 α ^{lo/-} OT-I cells were cultured for 3 d and 0.5×10^6 primary effector cells were transferred into WT or TL^{-/-} recipients. One month after transfer, mice were orally infected with 5×10^8 ActA⁻ Lm-OVA. 4 months p.i., memory OT-I cells were tracked in the spleens and IEL. Pooled data \pm s.e.m. are shown. At least two independent experiments were performed. (e, f) 5×10^4 naïve CD8⁺ OT-I cells were transferred into Ly5.1⁺ WT or Ly5.1⁺ TL^{-/-} recipient mice. 1 d after transfer, mice were orally infected with Lm-Q4OVA. Effector OT-I cells in the peripheral blood (7 d p.i.) and memory OT-I cells (2 m p.i.) in the spleen and IEL were analyzed. Pooled data \pm s.e.m. are shown. (g, h) 5×10^4 naïve CD8⁺ OT-I cells were transferred into Ly5.1⁺ WT or Ly5.1⁺ TL^{-/-} recipient mice. 1 d after transfer, mice were intravenously infected with Lm-Q4OVA. Effector OT-I cells in the peripheral blood (7 d p.i.) and memory OT-I cells (2 m p.i.) in the spleen and IEL were analyzed. Pooled data \pm s.e.m. are shown. At least three independent experiments were performed. (i) Ly5.1 mice adoptively transferred with 5×10^4 naïve WT or E8_I^{-/-} OT-I cells were orally immunized with $1 \times$


10^9 ActA⁻ Lm-OVA. Two months after immunization, mice were re-challenged orally with 1×10^{10} WT Lm-OVA. Bacterial loads in the livers were assessed day 3 p.i.. Pooled data \pm s.e.m. are shown ($n = 6$). Representative data are shown of three independent experiments. * $P < 0.05$; ns: no significant difference (unpaired t -test).

**Mucosal CD8 Memory T Cells are selected in the periphery
by an MHC Class I Molecule**



Yujun Huang^{1*}, Yunji Park^{1*}, Yiran Wang-Zhu¹, Alexandre Larange¹, Ramon Arens¹,
Iván Bernardo^{1,2}, Danyvid Olivares-Villagómez³, Dietmar Herndler-Brandstetter⁴, Ninan
Abraham⁵, Beatrix Grubeck-Loebenstein⁴, Stephen P. Schoenberger¹, Luc Van Kaer³,
Mitchell Kronenberg¹, Michael A. Teitell⁶ and Hilde Cheroutre¹

Supplementary Figures 1-6


Supplementary Figure 1





Supplementary Figure 2




Supplementary Figure 3




Supplementary Figure 4



Supplementary Figure 5



Supplementary Figure 6



Supplementary Figure Legends

Supplementary Figure 1. TL deletes activated CD8 $\alpha\beta$ ⁺ T cells. 1×10^6 naïve Ly5.1⁺ OT-I cells were transferred into WT or TL-Tg recipients. One day after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. Memory CD8⁺ OT-I cells in the livers were analyzed 2 month p.i.. Graph depicts pooled data \pm s.e.m.. *** $P < 0.001$ (unpaired *t*-test).

Supplementary Figure 2. MHC class II^{hi}, CD11c⁺ MLN DC have the phenotype of CCR7⁺ CD103⁺ migratory DC. (a) mLN contain a distinct MHC class II^{hi} DC subset that is absent in the spleen (dot plots). Surface expression of CCR7 and CD103 were analyzed on CD11c⁺MHC II⁺ DCs from SPL and CD11c⁺MHC II^{hi} or CD11c⁺MHC II^{int} DCs from mLN (histograms). Data are representative from at least three independent experiments. (b) Spleen or mLN DCs were sorted based on the CD11c and MHC II expression and used for mRNA quantification for TL expression by qRT-PCR. Data are representative from three independent experiments.

Supplementary Figure 3. Affinity-based selective programming of memory precursor cells does not require IL-7R signals. (a) Naïve CD8⁺ OT-I cells were cultured in the presence of APC (MEC.B7.SigOVA). CD8 $\alpha\alpha$ and IL-7R α expression on OT-I cells was determined by flow cytometry at different time points. (b) 1×10^4 naïve CD8⁺ WT OT-I cells or IL-7R α ^{449F} OT-I cells were adoptively transferred into Ly5.1 WT recipient mice. 1 d after transfer, mice were orally infected with 1×10^9 ActA⁻ Lm-OVA. Donor OT-I cells were tracked in the spleens and IEL 2 months p.i.. At least three independent experiments were performed.

Supplementary Figure 4. Expression of CD8 α and CD8 β on human CD8⁺ T cell subsets. The bar graphs show the relative percentage of CD8 α and CD8 β mean fluorescence intensity (MFI) in human CD8⁺T cell subsets ($n = 9$). ** $P < 0.01$ (unpaired t -test).

Supplementary Figure 5. Characterization of *in vitro* activated CD8 α^{hi} and CD8 $\alpha^{\text{lo/-}}$ CD8 $\alpha\beta^+$ T cells. (a) Naïve Ly5.1⁺ CD8⁺ OT-I cells were cultured in the presence of APC (MEC.B7.SigOVA). After two days' culture, CD8 α^{hi} and CD8 $\alpha^{\text{lo/-}}$ OT-I cells were sorted and cultured for 3 more days *in vitro*. Then 0.5×10^6 CD8 α^{hi} or CD8 $\alpha^{\text{lo/-}}$ were adoptively transferred into B6 recipients. 3 d after transfer, effector OT-I cell were tracked in the spleen and IEL. (b) Sorted CD8 α^{hi} and CD8 $\alpha^{\text{lo/-}}$ OT-I cells were directly stimulated with OVA₂₅₇₋₂₆₄ peptide for 5 h and intracellular staining for IFN- γ was performed. (c) 3 d after transfer of CD8 α^{hi} or CD8 $\alpha^{\text{lo/-}}$, *in vivo* cytotoxicity assay was performed in recipient mice. B6 splenocytes labeled as CFSE^{hi} and pulsed with OVA₂₅₇₋₂₆₄ peptide were used as target cells and splenocytes labeled as CFSE^{low} and pulsed with the control peptide were used as control target cells. Data are representative from three independent experiments.

Supplementary Figure 6. Proposed model for the roles of TL and CD8 α on selection of memory CD8 $\alpha\beta$ T cells. CD8 α expression is selectively induced on high affinity/avidity primary effector CD8 $\alpha\beta^+$ T cells and further enhanced by RA released by mucosal migratory (CCR7⁺) DC, which also promote gut-tropism ($\alpha 4\beta 7^+ \text{CCR}9^+$) of the effector T cells. Activated migratory DC express the CD8 α high affinity ligand, TL, which when interacting with CD8 $\alpha\beta$ on activated T cells leads to TICD. High affinity primary effector cells that induce CD8 α , escape TICD by sequestering TL away from CD8 $\alpha\beta$ via CD8 α leading to affinity-based selective survival. TL

constitutively expressed on the intestinal epithelial cells (IEC) mediates affinity maturation of the mucosal T_{EM} and eliminates low affinity/avidity primary and secondary effector cells that home to the gut and fail to induce CD8 α .

Figure 1




Figure 2





Figure 3

Figure 4




Figure 5




Figure 6




Figure 7